ganglioside--gd2 has been researched along with Nevus--Pigmented* in 1 studies
1 other study(ies) available for ganglioside--gd2 and Nevus--Pigmented
Article | Year |
---|---|
Expression of complement regulator proteins in primary and metastatic malignant melanoma.
The expression of complement regulatory antigens C3b/C4b receptor, (CD35) membrane cofactor protein (CD46), decay accelerating factor (CD55), and homologous restriction factor 20 (CD59) was determined immunohistochemically on ten primary malignant melanomas, 16 metastatic lesions, and ten melanocytic nevi. All of the melanocytic nevi and 9/10 primary melanomas showed both expression of CD46 and CD59. In one primary melanoma lacking CD46, expression of CD35 could be detected. In metastatic melanoma, 9/16 metastases were CD46+/CD59+, two were CD46-/CD59+, one CD46+/CD59-, and four CD46-/CD59-. Additionally, CD55 could be detected in two CD46+/CD59+ metastases, and CD35 in one. Expression or lack of complement regulatory antigens did not correlate with the expression of GD2, GD3, HMB-45 or S-100. In conclusion, some cases of metastatic melanoma show loss of normal expression of complement regulatory proteins. This might have implications on the immune response or the efficacy of immune therapy in malignant melanoma. Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Neoplasm; Child; Female; Gangliosides; Humans; Immunohistochemistry; Male; Melanoma; Melanoma-Specific Antigens; Middle Aged; Neoplasm Proteins; Nevus, Pigmented; S100 Proteins; Skin Neoplasms | 1999 |